SCHEMBL1492483

SCHEMBL1492483

O=C(Cc1ccccc1)N1CCCCC1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.69
HPGD P15428 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
TDP1 Q9NUW8 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.65
HSD11B1 P28845 1/20 0.65
ALDH1A1 P00352 6/20 0.64
KDM4E B2RXH2 2/20 0.64
POLB P06746 2/20 0.63
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
USP2 O75604 1/20 0.61
GAA P10253 1/20 0.61
TSHR P16473 1/20 0.61
ME2 P23368 1/20 0.59
ME1 P48163 1/20 0.59
ME3 Q16798 1/20 0.59
MAPT P10636 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8599235 1.00 NPC1 (0.69) NPC1HPGDSMN1; SMN2TDP1L3MBTL1
SCHEMBL874261 0.98 NPC1 (0.68) NPC1HPGDSMN1; SMN2TDP1L3MBTL1
Hydrochloric Acid SCHEMBL7223460 0.92 L3MBTL1 (0.65) NPC1HPGDSMN1; SMN2TDP1L3MBTL1
SCHEMBL10722408 0.90 HSD11B1 (0.77) HPGDSMN1; SMN2L3MBTL1HSD11B1ALDH1A1
SCHEMBL3967794 0.90 HSD11B1 (0.77) HPGDSMN1; SMN2L3MBTL1HSD11B1ALDH1A1
SCHEMBL6692812 0.86 NPC1 (0.58) NPC1HPGDSMN1; SMN2TDP1L3MBTL1
SCHEMBL5267307 0.85 HSD11B1 (0.70) HPGDSMN1; SMN2L3MBTL1HSD11B1ALDH1A1
SCHEMBL8672473 0.84 L3MBTL1 (0.56) NPC1HPGDSMN1; SMN2TDP1L3MBTL1
SCHEMBL1799311 0.84 POLB (0.68) NPC1HPGDSMN1; SMN2TDP1L3MBTL1
SCHEMBL4815795 0.83 NPC1 (0.51) NPC1HPGDSMN1; SMN2TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11171861-A None JP disclosed
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS AG (CH) 2024-07-25 US disclosed
US-20220111367-A1 HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME OSAKA UNIVERSITY (JP) 2022-04-14 US disclosed
US-9938415-B2 Functionalised antifouling compounds and use thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-04-10 US disclosed
US-9938415-B2 Functionalised antifouling compounds and use thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-04-10 US disclosed
US-20160311788-A1 Antifouling Compounds And Use Thereof NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-10-27 US disclosed
US-20160311788-A1 Antifouling Compounds And Use Thereof NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-10-27 US disclosed
US-20160311788-A1 Antifouling Compounds And Use Thereof NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-10-27 US disclosed
US-9284270-B2 Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids THE GOVERNERS OF THE UNIVERSITY OF ALBERTA (CA) 2016-03-15 US disclosed
US-9284270-B2 Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids THE GOVERNERS OF THE UNIVERSITY OF ALBERTA (CA) 2016-03-15 US disclosed
EP-1401821-A4 NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS SK CORP (KR) 2006-05-31 EP disclosed
EP-1401821-A1 NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS SK Corporation (KR) 2004-03-31 EP disclosed
WO-2002100848-A1 NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS SK CORPORATION (KR) 2002-12-19 WO disclosed
US-6127366-A ANTICARCINOGENIC OR ANTITUMOR AGENTS MERCK & CO., INC. (US) 2000-10-03 US disclosed
JP-H11171861-A PRODUCTION OF DONEPEZIL EISAI CO LTD 1999-06-29 JP disclosed
US-5817678-A IMIDAZOLE-CONTAINING PIPERIDINE DERIVATIVES, PEPTIDEMIMETIC MERCK & CO., INC. (US) 1998-10-06 US disclosed
EP-0654023-B1 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1998-09-16 EP disclosed
US-5523299-A ADMINISTERING IN TREATMENT OF PSYCHOTIC DISORDERS SMITHKLINE BEECHAM PLC (GB) 1996-06-04 US disclosed
EP-0654023-A1 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-05-24 EP disclosed
WO-1994003426-A1 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311788-A1 Antifouling Compounds And Use Thereof C5, C9, C1S NPC1 1720/4885HPGD 1719/4885SMN1; SMN2 3810/4885
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES IKZF1, IKZF2, IKZF3 NPC1 568/4885HPGD 3215/4885SMN1; SMN2 843/4885
US-20220111367-A1 HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME SUV39H2, SUV39H1, HRH3 NPC1 4484/4885HPGD 444/4885SMN1; SMN2 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.